SLC5A2 and Polyuria: The AEs associated with SGLT2 inhibition seen in other canagliflozin phase 3 studies 14–17, including genital mycotic infections, a small increase in UTIs (with no reports of upper UTI AEs), and AEs related to osmotic diuresis (i.e. pollakiuria and polyuria), were also seen in this study, although at lower rates, which may reflect the attenuation of UGE in this study population.